Comment from Biotechnology Innovation Organization (BIO)

Summary: The Biotechnology Innovation Organization (BIO) supports the FDA's initiative regarding Patient-Focused Drug Development (PFDD) meetings, highlighting how they provide valuable insights into patient experiences and disease burdens. They argue that these meetings foster collaboration, inform clinical trial designs, and create enduring resources that improve patient-centered drug development.